Skip to main content

Table 2 Mixed Model Analysis by Treatment, Sex, and Treatment by Sex for Predose and Postdose Time Points*

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

Time Point (hr)

Mixed Model Statistical Analysis

SKAMP-D

SKAMP-A

SKAMP-Total

SKAMP-QoL

PERMP-A

PERMP-C

  

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

-0.5

Treatment

0.99

.3230

7.21

.0084

28.52

<.0001

93.12

<.0001

22.19

<.0001

23.58

<.0001

 

Sex

9.36

.0028

8.71

.0039

13.38

.0004

0.75

.3891

0.31

.5809

0.25

.6164

 

Treatment by sex

1.95

.1657

0.19

.6620

2.49

.1173

0.52

.4714

0.59

.4447

0.76

.3861

1.5

Treatment

19.58

<.0001

12.45

.0006

28.01

<.0001

1.06

.3049

13.67

.0003

19.73

<.0001

 

Sex

6.59

.0116

3.50

.0639

7.84

.0060

3.72

.0562

0.37

.5421

0.48

.4899

 

Treatment by sex

0.00

.9779

0.10

.7528

0.20

.6578

0.88

.3493

0.05

.8245

0.39

.5315

2.5

Treatment

70.77

<.0001

53.15

<.0001

131.44

<.0001

43.18

<.0001

60.11

<.0001

65.68

<.0001

 

Sex

7.89

.0059

2.35

.1278

8.72

.0038

2.88

.0928

0.39

.5326

0.39

.5350

 

Treatment by sex

2.71

.1023

0.81

.3708

2.97

.0875

0.15

.6995

1.10

.2975

1.62

.2063

5.0

Treatment

74.56

<.0001

50.75

<.0001

136.60

<.0001

68.23

<.0001

73.30

<.0001

76.40

<.0001

 

Sex

7.13

.0087

2.58

.1111

7.00

.0093

0.20

.6518

0.23

.6357

0.18

.6708

 

Treatment by sex

2.50

.1166

1.33

.2517

1.63

.2049

0.28

.5949

1.18

.2801

1.40

.2398

7.5

Treatment

67.32

<.0001

56.67

<.0001

137.48

<.0001

53.75

<.0001

89.27

<.0001

92.70

<.0001

 

Sex

9.38

.0028

3.52

.0633

11.68

.0009

10.46

.0016

1.65

.2021

1.73

.1916

 

Treatment by sex

4.31

.0402

2.10

.1506

4.16

.0438

0.24

.6248

0.92

.3406

0.76

.3855

10

Treatment

44.74

<.0001

39.70

<.0001

92.89

<.0001

17.42

<.0001

64.41

<.0001

69.95

<.0001

 

Sex

8.67

.0039

5.07

.0263

13.35

.0004

3.22

.0754

0.65

.4233

0.69

.4083

 

Treatment by sex

1.51

.2222

3.67

.0579

6.31

.0135

2.86

.0939

5.43

.0217

4.98

.0277

12

Treatment

21.05

<.0001

30.04

<.0001

69.72

<.0001

26.38

<.0001

47.55

<.0001

52.36

<.0001

 

Sex

14.36

.0002

2.33

.1299

12.84

.0005

0.67

.4165

0.34

.5613

0.36

.5484

 

Treatment by sex

0.93

.3374

0.37

.5455

0.55

.4586

0.31

.5767

1.32

.2524

1.42

.2357

13

Treatment

3.70

.0568

19.09

<.0001

21.25

<.0001

8.13

.0052

39.39

<.0001

41.15

<.0001

 

Sex

12.45

.0006

2.84

.0945

13.56

.0004

1.53

.2187

1.08

.3012

1.37

.2439

 

Treatment by sex

1.30

.2571

2.69

.1039

3.03

.0844

0.00

.9942

3.58

.0609

2.74

.1006

  1. LDX: lisdexamfetamine dimesylate; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
  2. *Degrees of freedom (df) = 110 for all analyses except the 7.5-hour postdose time point where df = 109 for all analyses.
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000